



# AFFINITY

## HealthCare Worldwide Growth Trust

30 April 2007

### Background


The fund was introduced by Calan HealthCare in 1999 to give NZ investors an exposure to worldwide developments in health care technology. AXA Framlington sub-manage the fund through a wholesale investment in a UK domiciled Health Fund. The fund is not currency hedged which has been a major head wind over the last five years. This combined with the biotechnology boom and bust cycle have created tax loss of over \$NZ 4 million to carry forward and offset against future taxable income.

Investments are in the producers of pharmaceuticals, bio-technology firms, medical device and instrument manufacturers, distributors of health-care products, care providers and healthcare services companies. 78% of the fund is exposed to companies based in the US. The fund favours the small to mid cap. companies being the focus of M&A activity from large pharmaceutical companies that typically have patent expiration issues and a lack of new product pipeline.

We do not believe past performance is a reasonable guide to the potential performance of the fund. April has not been great as the large US pharmaceuticals have outperformed and we have no existing exposure. Foreign exchange continues to be an issue.

### Top Ten Holdings

31 March 2007



### Fund Facts - as at 24/3/07

Price	\$NZ 1.04
Fund size	\$NZ 5 million
Launch date	27/08/1999
Price Launch	\$NZ 1.00
Price highest	29/09/2000 \$NZ 2.39
Price lowest	12/03/2003 \$NZ 0.76

### Sub-Sector Allocation

31 March 2007

